Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth

Alfredo Martínez, Enrique Zudaire, Sergio Portal-Núñez, Liliana Guédez, Steven K. Libutti, William G. Stetler-Stevenson, Frank Cuttitta

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

We have found through ex vivo and in vivo angiogenesis models that the adrenomedullin gene-related peptide, proadrenomedullin NH2-terminal 20 peptide (PAMP), exhibits a potent angiogenic potential at femtomolar concentrations, whereas classic angiogenic factors such as vascular endothelial growth factor and adrenomedullin mediate a comparable effect at nanomolar concentrations. We found that human microvascular endothelial cells express PAMP receptors and respond to exogenous addition of PAMP by increasing migration and cord formation. Exposure of endothelial cells to PAMP increases gene expression of other angiogenic factors such as adrenomedullin, vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived growth factor C. In addition, the peptide fragment PAMP(12-20) inhibits tumor cell-induced angiogenesis in vivo and reduces tumor growth in xenograft models. Together, our data demonstrate PAMP to be an extremely potent angiogenic factor and implicate this peptide as an attractive molecular target for angiogenesis-based antitumor therapy.

Original languageEnglish (US)
Pages (from-to)6489-6494
Number of pages6
JournalCancer Research
Volume64
Issue number18
DOIs
Publication statusPublished - Sep 15 2004

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Martínez, A., Zudaire, E., Portal-Núñez, S., Guédez, L., Libutti, S. K., Stetler-Stevenson, W. G., & Cuttitta, F. (2004). Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth. Cancer Research, 64(18), 6489-6494. https://doi.org/10.1158/0008-5472.CAN-04-0103